<DOC>
	<DOCNO>NCT02592031</DOCNO>
	<brief_summary>Aim study demonstrate bioequivalence single subcutaneous dos XM17 Gonal-f® confirmatory design . Furthermore , safety tolerability assess human healthy female subject . Only female subject include study reach objective study .</brief_summary>
	<brief_title>Study Compare Bioavailability , Safety Tolerability XM17 Healthy , Down Regulated Young Women</brief_title>
	<detailed_description />
	<mesh_term>Goserelin</mesh_term>
	<criteria>Having sign write informed consent Healthy female subject racial origin 1839 year time screen Body mass index ( BMI ) 1829 kg/m2 body weight ≥ 50 kg Use oral contraceptive contraceptive purpose regularization menstrual cycle , least 3 month Normal uterus two function ovary Agrees use adequate method contraception study Nonsmoking moderate smoker &lt; 10 cigarette day Pregnancy Polycystic ovary syndrome , impaired ovarian function , severe endometriosis class III IV , submucosal myoma uteri History endocrine abnormality treatment within last six month . Contraindications use gonadotropin goserelin Breastfeeding within period 2 month delivery abortion . Use injectable hormonal contraceptive within period 6 month prior screen Treatment previous three month drug know welldefined potential toxicity major organ</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>